Commercially insured PATIENTS MAY Pay $0 for their first INTRAROSA  prescription Click here


Eligible commercially insured patients pay as little as a:
$0 copay for the first 28-day supply
Maximum saving limits apply. Patient out-of-pocket expense may vary.*
Patient Savings card
*Offer valid on up to 12 uses for commercially insured patients with a valid prescription for INTRAROSA. A valid prescriber ID# is required on the prescription. Limitations apply. Click here for full Terms and Conditions.
See More


INTRAROSA is a steroid indicated for the treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy, due to menopause.

Important Safety Information

INTRAROSA is contraindicated in women with undiagnosed abnormal genital bleeding.

Estrogen is a metabolite of prasterone. Use of exogenous estrogen is contraindicated in women with a known or suspected history of breast cancer. INTRAROSA has not been studied in women with a history of breast cancer.

In four 12-week randomized, placebo-controlled clinical trials, the most common adverse reaction with an incidence ≥2 percent was vaginal discharge. In one 52-week open-label clinical trial, the most common adverse reactions with an incidence ≥2 percent were vaginal discharge and abnormal Pap smear.

To report SUSPECTED ADVERSE REACTIONS, contact Millicent Pharma at 1­-877-810-2101 or FDA at 1-800­-FDA-1088 or

Please see full Prescribing Information.